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Aims: Clusterin is a topologically dynamic chaperone
protein with the ability to participate in both intra-
and extacellular proteostasis. Clusterin has been
shown to be upregulated in the spinal cord of patients
with amyotrophic lateral sclerosis (ALS) and has been
shown to protect against TDP-43 protein misfolding in
animal and cell models. Previous studies have demon-
strated an association between the pathological burden
of TDP-43 misfolding and cognitive deficits in ALS,
demonstrating high specificity, but correspondingly
low sensitivity owing to a subset of individuals with
no evidence of cognitive deficits despite a high burden
of TDP-43 pathology, called mismatch cases. Methods:
Hypothesizing that differences in the ability to cope
with protein misfolding in these cases may be due to
differences in expression of protective mechanisms
such as clusterin expression, we assessed the spatial
expression of clusterin and another chaperone protein,
HspB8, in post mortem brain tissue of mismatch cases.
We employed a modified in situ hybridization tech-
nique called BaseScope, with single cell, single
transcript resolution. Results: Mismatch cases demon-
strated differential spatial expression of clusterin, with
a predominantly neuronal pattern, compared to cases
with cognitive manifestations of their TDP-43 pathol-
ogy who demonstrated a predominantly glial distribu-
tion of expression. Conclusions: Our data suggest that,
in individuals with TDP-43 pathology, predominantly
neuronal expression of clusterin in extra-motor brain
regions may indicate a cell protective mechanism
delaying clinical manifestations such as cognitive
dysfunction.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive
neurodegenerative disease characterized by muscle den-
ervation and atrophy leading to paralysis and death.
These motor features are often accompanied by
cognitive dysfunction in as many as 50% of ALS
patients with up to 15% of patients exhibiting features
of frontotemporal dementia (FTD) [1–3]. Despite this
clinical heterogeneity, a unifying pathological feature
seen in the majority of ALS and FTD patients is the
presence of the 43 kDa Tar-DNA binding protein (TDP-
43), whose pathological misfolding and accumulation
is observed in the brains and spinal cord of the major-
ity of ALS patients with the notable exception of ALS
cases caused by SOD1 mutation [4]. TDP-43 is a pre-
dominantly nuclear protein involved in transcriptional
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regulation. In ALS post mortem brain and spinal cord
tissue, TDP-43 is found to be pathologically phosphory-
lated and C-terminally truncated in cytoplasmic aggre-
gates [5]. The toxicity conferred by TDP-43 in ALS is
thought to be partly loss-of-function caused by seques-
tration in insoluble aggregates limiting transcriptional
regulation, and partly due to a gain-of-function where
cytotoxic cytoplasmic aggregates can lead to the dys-
regulation of proteostasis and sequester other aggrega-
tion prone proteins causing further cytotoxicity and
contributing to cell death [6].
Protein misfolding, aggregation and subsequent cell
death are common pathways in all neurodegenerative
diseases exhibiting cognitive phenotypes. However,
cognitive defects in ALS, while common, typically
affect multiple domains and there is a distinctive cog-
nitive profile in ALS compared to other neurodegener-
ative diseases, and cognition is therefore best assessed
by an ALS specific cognitive test such as the Edin-
burgh Cognitive ALS Screen (ECAS). The ECAS is a
neuropsychological assessment specifically designed to
assess the cognitive deficits associated with ALS, nota-
bly (i) verbal fluency, (ii) executive function and (iii)
language [7]. It also comprises assessment of visu-
ospatial and memory assessments that are typically
disordered in other neurodegenerative diseases such as
Alzheimer’s disease. The ECAS provides high sensitiv-
ity and specificity using published cut off scores for
abnormality (7). ECAS has been validated extensively
in many different diverse populations of ALS and FTD
patients [8–11] and against other neuropsychological
batteries [12,13].
While several studies have shown an association
between TDP-43 pathology and cognitive deficits, these
studies have consistently identified a subgroup of
patients who have abundant TDP-43 pathology and no
corresponding cognitive defects [14,15]. These cases
are called mismatch cases, due to the mismatch
between the abundant pathology and corresponding
lack of clinical manifestations. Importantly, previous
studies have overlooked protective mechanisms that
may be at play in these cases. In response to protein
aggregation and subsequent dysregulation of proteosta-
sis, cellular mechanisms, including the upregulation of
chaperone proteins, are initiated to reduce the cytotoxic
burden of these misfolded proteins. Our hypothesis,
therefore, is that the heterogeneity seen in the cogni-
tive and pathological manifestations of ALS, may, in
part reflect individual differences in the balance
between proteotoxic stress and protective mechanisms.
The aim of this study was to characterize the expres-
sion of two such putative protective mechanisms, the
expression of two chaperone proteins, clusterin and
HspB8, known to protect against TDP-43 pathology
[16,17]. Clusterin responds to protein misfolding stress
by retrotranslocating from its normal extracellular dis-
tribution to the intracellular compartment [18], where
it can directly interact with TDP-43, (i) preventing its
aggregation, and (ii) restoring TDP-43 to its normal
nuclear localization [16]. HspB8 is an intercellular
chaperone protein, whose role in proteostasis is well-
established in reducing TDP-43-associated proteotoxic-
ity [16,19,20].
Within our cohort of ALS brain bank patients, 27
patients had undergone standardized cognitive testing
using ECAS during life. Of these 27 patients, following
in depth neuropathological assessment of TDP-43
pathology, we were able to identify six patients who fit
the classification of a mismatch case, with abundant
TDP-43 pathology and a normal ECAS score. For com-
parison, we identified 11 cases who had TDP-43
pathology with evidence of mild cognitive deficits.
Within this cohort we analysed the spatial expression
of clusterin and HspB8, with single cell, single tran-
script resolution, employing a novel modified in situ
hybridization technique called BaseScope. In doing this,
we demonstrate spatial expression differences in clus-
terin between cases with cognitive deficits and mis-
match cases without cognitive manifestations,
highlighting an important protective mechanism.
Methods
Case identification
We identified, from the Medical Research Council
(MRC) Edinburgh Brain Bank, a cohort of 17 ALS
patients for neuropathological assessment, all of whom
had undergone standardized cognitive testing using the
ECAS and demonstrated TDP-43 in nonmotor brain
regions at post mortem. In our analysis, we sought to
assess protective mechanisms (cell-type specific clus-
terin and HspB8 expression). All clinical data including
the ECAS were collected as part of Scottish Motor Neu-
rone Disease Register (SMNDR) and Care Audit
Research and Evaluation for Motor Neurone Disease
© 2019 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
2 J. M. Gregory et al.
(CARE-MND) platform (ethics approval from Scotland A
Research Ethics Committee 10/MRE00/78 and 15/SS/
0216) and all patients consented to the use of their
data during life. Control brains were selected from the
sudden death brain bank and therefore have not died
of a chronic illness or neurological condition. All con-
trol cases are rigorously assessed by experts, both clini-
cally and neuropathologically, to rule out any evidence
of disease, including the use of an extensive standard-
ized panel of immunohistochemistry, with pathology
being assessed using well-defined and published grading
systems. All post mortem tissue was collected via the
Edinburgh Brain Bank (ethics approval from East of
Scotland Research Ethics Service, 16/ES/0084) in line
with the Human Tissue (Scotland) Act. Use of human
tissue for post mortem studies has been reviewed and
approved by the Edinburgh Brain Bank ethics commit-
tee and the Academic and Clinical Central Office for
Research and Development (ACCORD) medical research
ethics committee (AMREC).
TDP-43 neuropathological analysis
Brain tissue was taken at post mortem from standard-
ized Brodmann areas (BA) relating to cognitive dys-
function in ALS (BA44/45 was selected for its role in
language and fluency function and BA46 for its role in
executive and fluency) and fixed in 10% formalin for a
minimum of 24 h. Tissue was dehydrated in an
ascending alcohol series (70–100%) followed by three
successive 4-h washes in xylene. Three successive five-
hour paraffin wax embedding stages were performed
followed by cooling and sectioning of the formalin-fixed
paraffin embedded (FFPE) tissue on a Leica microtome
in 4-lm sections on to a superfrost microscope slide.
Sections were dried overnight at 40°C and immunos-
taining was performed using the Novolink Polymer
detection system with the proteintech anti-phospho
(409-410)-TDP-43 antibody at a 1 in 1000 dilution
and DAB chromogen and counterstained with haema-
toxylin, according to standard operating procedures. As
previous studies have demonstrated no difference in or
effect of relative abundance of TDP-43 pathology with
cognitive manifestations [11], the slides were reviewed
by two independent pathologists for presence or
absence of TDP-43 pathology only. Cell morphology
was used to differentiate (i) glial cells (with small 4–
5 µm) oval to round nuclei and a small quantity of
surrounding cytoplasm. Neurons were classified as such
if they had larger nucleus (5–10 µm) and a larger
quantity of blue cytoplasm forming peripheral processes
(stained using haematoxylin counterstain).
BaseScope analysis – assessing spatial expression of
clusterin and HspB8
FFPE tissue was sectioned at 4 lm thickness on to
superfrost slides. BaseScope reagents (Advanced Cell
Diagnostics) were used as per the manufacturer’s guide-
lines according to the original protocol [21]. In brief,
following deparaffinization, tissue sections were incu-
bated with hydrogen peroxide for 10 min at room tem-
perature and target antigen retrieval was performed by
submerging slides in BaseScope 1X target retrieval
reagent at 99°C in a Braun Multiquick FS 20 steamer
for 15 min. The tissue was then permeabilized using
BaseScope protease III at 40°C for 30 min. Probe
hybridization was then performed by incubating the
slides with four drops of custom designed BaseScope
probe (to recognize clusterin/HspB8 mRNA transcripts),
negative control probe (DapB) or positive control (PPIB)
probe for 2 h at 40°C. Following successive probe
amplification steps, transcripts were detected using the
BaseScope RED detection kit and slides were counter-
stained using haematoxylin and lithium carbonate. The
slides were then cleared in xylene and mounted with a
24 9 50 mm coverslip using two drops of VectaMount
mounting medium. Sections were then imaged at 20x
magnification on a NanoZoomer slide scanner and rela-
tive abundance of transcripts was quantified by two
independent pathologists. One-way ANOVA (with Bon-
ferroni correction for multiple comparisons) was used
to analyse clusterin expression (Figure 2).
Results
Subgroups of patients exhibiting TDP-43 pathology
with no cognitive impairment have differential
spatial expression of clusterin
Within our cohort of 27 patients who had undergone
ECAS testing during life, we identified a subgroup of six
patients that demonstrated no cognitive impairment
when assessed by the ECAS, but did exhibit extra-motor
TDP-43 pathology when assessed at post mortem, so
called mismatch cases, and 11 patients who had TDP-
© 2019 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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43 and corresponding cognitive dysfunction; one with
executive dysfunction, two with fluency dysfunction,
six with language dysfunction and two with a mixed
cognitive deficit (Table 1). The median survival (from
onset of disease) of the mismatch cases, 71 months
(range: 16–159), was not statistically significantly dif-
ferent from individuals where the ECAS did accurately
predict TDP-43 pathology, 58 months (range: 13–150)
(Mann–Whitney U test: U-value = 26; Z-
score = 0.65327; P = 0.5157), suggesting that dis-
ease duration was not likely to be playing a significant
role in the clinical manifestations of TDP-43 pathology
in these cases. Furthermore, the time between ECAS
testing and death was not significantly different
between the two groups. The group with no cognitive
impairment was comprised of four individuals assessed
within one year of death and two individuals with
more than a one-year gap between ECAS testing and
death. The group with cognitive impairment was com-
prised of six individuals assessed within one year of
death and five individuals with more than a one-year
gap between ECAS testing and death. Fisher’s exact test
revealed no significant difference between these two
groups as the two-tailed p value equates to 0.6004.
Two mismatch cases had an underlying genetic muta-
tion, both of which were a C9orf72 hexanucleotide
repeat expansion (30%), compared to five genetic
mutations (four C9orf72 and one NEK1 mutation) in
the 11 comparison cases with cognitive deficits (45%).
Fisher’s exact test revealed no significant difference
between these two groups as the two-tailed p value
equates to 1.0000.
Given that these mismatch cases had pathologically
misfolded TDP-43 in extra-motor brain regions without
suffering clinical manifestations at the time of ECAS
assessment during life, we wanted to investigate if they
Table 1. Summary of cohort demographics including genetics, median survival from symptom onset, time from ECAS to PM and gender
TDP-43 pathology with no evidence of
cognitive dysfunction (mismatch cases)
TDP-43 pathology with evidence
cognitive dysfunction
Statistics(n = 6) (n = 11)
Genetics C9orf72: 2 cases C9orf72: 4 cases Fisher’s exact test
P = 1.0000NEK1: 1 case
Median survival (from
symptom onset)
71 months (range: 16–159) 58 months (range: 13–150) Mann–Whitney U:
P = 0.5157
Time from ECAS to PM Four individuals assessed within one
year of death and two individuals with
more than a one year gap between
ECAS testing and death.
Six individuals assessed within
one year of death and five
individuals with more than a




Gender Male = 4 Male = 7 Fisher’s exact test
P = 1.0000
Female = 2 Female = 4
Figure 1. Individuals with TDP Pathology but no associated cognitive impairment exhibit predominantly neuronal expression of
clusterin. (A). Graph quantifying grey matter neuronal and glial expression and white matter glial expression of clusterin, in the BA46
region associated with executive function, in cases with TDP-43 pathology and cognitive deficits (TDP-43+, Cognitive deficit+), mismatch
cases (TDP-43+, Cognitive deficit-) and three non-ALS/non-neurological control cases (TDP-43-, Cognitive deficit-); demonstrating
upregulation of clusterin in all ALS cases, with predominantly glial expression in cases with TDP-43 pathology and corresponding
cognitive deficits and predominantly neuronal expression in mismatch cases. *Indicates P < 0.001, one-way ANOVA with Bonferroni
correction for multiple comparisons (n = 3 patients per group; 10 cells in each of 3 randomly selected high power fields of view were
assessed per case). (B) Same as A but assessing the BA44 region associated with language and fluency. *Indicates P < 0.001, one-way
ANOVA with Bonferroni correction for multiple comparisons (n = 3 patients per group; 10 cells in each of 3 randomly selected high
power fields of view were assessed per case). (C) Representative region of the brain associated with executive function (BA46),
demonstrating striking difference in expression of the chaperone protein clusterin between cases with and without cognitive dysfunction.
Black arrows indicate glial expression, red arrows indicate neuronal expression, blue arrows indicate neuropil staining that is not
associated with glial cells consistent with neuronal expression. Scale bars = 50 µm. (D) Representative region of the brain associated
with language and fluency (BA44), demonstrating striking difference in expression of the chaperone protein clusterin between cases with
and without cognitive dysfunction. Black arrows indicate glial expression, red arrows indicate neuronal expression and blue arrows
indicate neuropil staining that is not associated with glial cells consistent with neuronal expression. Scale bars = 50 µm.
© 2019 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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had upregulation of compensatory, protective mecha-
nisms that could account for this altered protein mis-
folding capacity and which would allow for this high
burden of protein misfolding to be tolerated. We
assessed the expression of two chaperone proteins: clus-
terin and HspB8, both known to protect neurones from
intracellular protein misfolding stresses, and more
specifically known to protect against TDP-43 proteotox-
icity [16,17]. For this analysis, we selected the same
brain regions as above; BA46 and BA44/45.
As previously demonstrated, clusterin expression was
increased in all ALS cases assessed compared to age-
and sex-matched controls with no clinical or pathologi-
cal evidence of neurological disease (Figure 1A,B) [16].
In the mismatch cases, there is high expression of clus-
terin in the neuronal cells, with correspondingly low
levels of expression in the glial cells (Figure 1). This is
strikingly different to the individuals with TDP-43
pathology who do have cognitive deficits, as these indi-
viduals have high levels of glial expression, with very
little neuronal expression (Figure 1C,D). Cell-type speci-
fic expression of clusterin was quantified in representa-
tive brain regions using BaseScope analysis, allowing
for the direct visualization of single mRNA transcripts
at a single cell level. This revealed a statistically signifi-
cant increase in expression of neuronal clusterin in
mismatch cases (P < 0.001, two-way ANOVA with
Bonferroni correction for multiple comparisons) and a
statistically significant increase in expression of glial
clusterin in cases with TDP-43 pathology with a cogni-
tive deficit (P < 0.001, two-way ANOVA with Bonfer-
roni correction for multiple comparisons; Figure 2A,B).
HspB8 is another chaperone protein, which was used
as a comparator whose intracellular role in proteostasis
is well-established in reducing TDP-43-associated pro-
teotoxicity [17,19,20]. However, HspB8, while statisti-
cally significantly upregulated in the white matter glia
of ALS cases with TDP-43 pathology compared to non-
neurological controls (Figure 2A,B), unlike clusterin,
was not differentially regulated between individuals
with or without cognitive deficits. Furthermore, given
the differential expression pattern of HspB8 was noted
to be in the white matter glia, this pattern more likely
reflects reactive gliosis and unlike clusterin is not spa-
tially dysregulated between cognitively impaired and
cognitively intact individuals (Figure 2C).
Discussion
While there is evidence to suggest a statistically signifi-
cant association of cognitive deficits in ALS with TDP-
43 pathology [14,15], in these published datasets there
is a subset of individuals with evidence of substantial
TDP-43 pathology with no evidence of cognitive dys-
function, so called mismatch cases. Indeed, these mis-
match cases are not unique to the clinical phenotype
caused by TDP-43 pathology as similar mismatch cases
have been identified in other cohorts including Alzhei-
mer’s cases with substantial misfolded amyloid and tau
deposits, with no concomitant cognitive deficits and the
ALS-PDC cluster on Guam where there were cases with
substantial tau neurofibrillary tangles with no associ-
ated cognitive deficits [22,23]. Our findings advance
the field further by demonstrating the importance of
looking not just at the pathological processes (TDP-43
misfolding) but also assessing the opposing, potentially
protective mechanisms (e.g. clusterin expression) that
some individuals mount to enable them to cope with
the apparent neurotoxic insult of protein misfolding.
The ability to express high levels of neuronal clusterin,
could be affording these cells some neuroprotection and
reducing the clinical manifestations of the disease that
would be associated with neurotoxicity of TDP-43
accumulation in these regions. High glial expression of
Figure 2. HspB8 expression is upregulated in the white matter glia of ALS patients compared to controls. (A) Graph quantifying grey
matter neuronal and glial expression and white matter glial expression of HspB8, in the BA46 region associated with executive function,
in cases with TDP-43 pathology and cognitive deficits (TDP-43+, Cognitive deficit+), mismatch cases (TDP-43+, Cognitive deficit-) and
three non-ALS/non-neurological control cases (TDP-43-, Cognitive deficit-); demonstrating upregulation of HspB8 in the white matter glia
of all ALS cases exhibiting TDP-43 pathology. ***Indicates P < 0.001, *Indicates P < 0.05, one-way ANOVA with Bonferroni correction
for multiple comparisons (n = 3 patients per group; 10 cells in each of 3 randomly selected high power fields of view were assessed per
case). (B) Same as A but assessing the BA44 region associated with language and fluency. *Indicates P < 0.05, two-way ANOVA with
Bonferroni correction for multiple comparisons (n = 3 patients per group; 10 cells in each of 3 randomly selected high power fields of
view were assessed per case). (C) Representative region of the brain associated with executive function (BA46), demonstrating neuronal
(red arrows) and glial (black arrows) expression of HspB8, with increased HspB8 expression within white matter glia. Scale
bars = 50 µm. (D) Representative region of the brain associated with language and fluency (BA44), demonstrating neuronal (red
arrows) and glial (black arrows) expression of HspB8, with increased HspB8 expression within white matter glia. Scale bars = 50 µm.
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clusterin in the patients with TDP-43 pathology and
cognitive deficits could also reflect high levels of reac-
tive gliosis resulting from axonal degeneration and cell
death. Moreover, taking account of the HspB8 results,
these findings suggest that the cell-type specific dysreg-
ulation of clusterin distinguishes between individuals
with or without cognitive deficits and is specific to clus-
terin and not simply reflecting an underlying reactive
process. However, given this is post mortem tissue, it is
uncertain whether the differential expression of clus-
terin is (i) the cause of, or (ii) a consequence of the dif-
ferent cognitive-pathological phenotypes, although, it is
clear, that there are striking differences in putative pro-
tective cellular mechanisms in these patients.
Stratifying patients for clinical trials based on cogni-
tion, would be beneficial as the high specificity would
result in only patients with definite TDP-43 pathology
being recruited. However, this approach, owing to
reduced sensitivity, would fail to identify mismatch
cases, that could also benefit from therapies targeting
TDP-43 misfolding. Our findings here, suggest that
these mismatch cases could instead be identified by
clusterin phenotyping, in addition to cognitive testing,
as, the striking differential expression of clusterin could
be a target for biomarker development. Clusterin is a
normally secreted chaperone protein, with the ability to
retrotranslocate to the cytosol under conditions of
intracellular stress, such as TDP-43 misfolding and
accumulation [16]. In fact, clusterin levels in both cere-
brospinal fluid (CSF) and plasma have been investigated
for other neurodegenerative diseases and a recent mass
spectrometry analysis of plasma from patients with ALS
showed that clusterin levels were able to distinguish
between non-neurological controls and cognitively
impaired ALS patients [24,25]. It is therefore possible
that clusterin could be used in conjunction with cogni-
tive testing with tests such as the ECAS, to improve the
sensitivity of the detection of TDP-43 pathology in non-
motor brain regions, in ALS patients and improve (i)
prognostication regarding risk of developing cognitive
impairment and (ii) stratification for clinical trials.
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